Targeting aggrephagy for the treatment of Alzheimer’s disease

Sandeep Malampati, Ju Xian Song, Benjamin Chun Kit Tong, Anusha Nalluri, Chuan Bin Yang, Ziying Wang, Sravan Gopalkrishnashetty Sreenivasmurthy, Zhou Zhu, Jia Liu, Chengfu Su, Senthilkumar Krishnamoorthi, Ashok Iyaswamy, King Ho Cheung, Jia Hong Lu, Min Li

Research output: Contribution to journalReview articlepeer-review


Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases in older individuals with specific neuropsychiatric symptoms. It is a proteinopathy, pathologically characterized by the presence of misfolded protein (Aβ and Tau) aggregates in the brain, causing progressive dementia. Increasing studies have provided evidence that the defect in protein-degrading systems, especially the autophagy-lysosome pathway (ALP), plays an important role in the pathogenesis of AD. Recent studies have demonstrated that AD-associated protein aggregates can be selectively recognized by some receptors and then be degraded by ALP, a process termed aggrephagy. In this study, we reviewed the role of aggrephagy in AD development and discussed the strategy of promoting aggrephagy using small molecules for the treatment of AD.

Original languageEnglish (US)
Article number311
Issue number2
StatePublished - Feb 2020
Externally publishedYes


  • Aggregates
  • Aggrephagy
  • Alzheimer’s disease
  • Selective autophagy

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Targeting aggrephagy for the treatment of Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this